Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Raw Materials (2021 - 2025)

Universe Pharmaceuticals' Raw Materials history spans 5 years, with the latest figure at $2.5 billion for Q3 2025.

  • For Q3 2025, Raw Materials rose 245.78% year-over-year to $2.5 billion; the TTM value through Sep 2025 reached $2.5 billion, up 245.78%, while the annual FY2025 figure was $2.5 billion, 245.78% up from the prior year.
  • Raw Materials for Q3 2025 was $2.5 billion at Universe Pharmaceuticals, up from $720.0 million in the prior quarter.
  • Across five years, Raw Materials topped out at $2.5 billion in Q3 2025 and bottomed at $16701.0 in Q3 2022.
  • The 5-year median for Raw Materials is $635395.0 (2023), against an average of $642.2 million.
  • The largest annual shift saw Raw Materials plummeted 97.25% in 2022 before it skyrocketed 113221.79% in 2024.
  • A 5-year view of Raw Materials shows it stood at $607661.0 in 2021, then tumbled by 97.25% to $16701.0 in 2022, then skyrocketed by 3704.53% to $635395.0 in 2023, then surged by 113221.79% to $720.0 million in 2024, then skyrocketed by 245.78% to $2.5 billion in 2025.
  • Per Business Quant, the three most recent readings for UPC's Raw Materials are $2.5 billion (Q3 2025), $720.0 million (Q3 2024), and $635395.0 (Q3 2023).